Pure primary signet ring cell carcinoma breast: A rare cytological diagnosis

Sandhu, Jashan; Dubey, V K; Makkar, Manisha; Suri, Vijay

doi:10.4103/0970-9371.117646

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings showed no significant difference in age and sex ratio between SRCC and MBC patients. In addition, the incidence of the two types of tumors was higher in elderly patients, which is consistent with findings from other studies (15,16). Previous studies report that high-grade tumors were more common in the SRCC group compared with the MBC group (17,18).…”

Section: Discussionsupporting

confidence: 91%

Prognostic Analysis of Primary Breast Signet Ring Cell Carcinoma and Mucinous Breast Adenocarcinoma: A SEER Population-Based Study

Wang¹,

Zhang

Yin³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPrimary breast signet ring cell carcinoma (SRCC) is a rare type of breast cancer with typical morphological characteristics, high aggressiveness, and poor prognosis. SRCC is different from mucinous breast adenocarcinoma (MBC). However, only a few studies have explored the clinicopathological features and prognosis of SRCC and MBC.MethodsData retrieved from the Surveillance, Epidemiology, and End-Results (SEER) database (2004–2015) were used to explore the prognostic effect of clinicopathological features and treatment modalities on survival outcomes of SRCC and MBC patients. Kaplan–Meier plot analysis, multivariate Cox proportional risk model, propensity score matching (PSM), and subgroup analysis were performed.ResultsA total of 167 patients with SRCC and 11,648 patients with MBC were included in the study. SRCC patients exhibited higher histological grade (p < 0.001), larger tumor volume (p < 0.001), higher rate of lymph node metastasis (p < 0.001), and higher frequency of distal metastasis (p < 0.001) compared with MBC patients. Cox proportional hazards regression analysis showed that SRCC patients had lower overall survival (OS) and breast cancer-specific survival (BCSS) compared with MBC patients. Subgroup survival analysis showed that the SRCC patients had lower OS and BCSS in subgroups including younger than 60 years old, white race, married, without chemotherapy, and received radiotherapy compared with the MBC patients in these subgroups. In addition, the SRCC patients had lower BCSS in subgroups including other races (including Asian or Pacific Islander and American Indian/Alaska Native), without surgery, and lymph node metastasis.ConclusionThe findings showed that primary breast SRCC patients have unique clinical characteristics and worse prognosis compared with MBC patients. Notably, different treatment methods resulted in different prognosis for SRCC and MBC types; therefore, SRCC patients should be distinguished from MBC patients to improve efficacy of treatment.

show abstract

Section: Discussionsupporting

confidence: 91%

Prognostic Analysis of Primary Breast Signet Ring Cell Carcinoma and Mucinous Breast Adenocarcinoma: A SEER Population-Based Study

Wang¹,

Zhang

Yin³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Although placed under the same subtype of carcinoma as mucinous breast cancer (MBC), different morphology and biologic behavior between these two types of mucin-producing carcinoma has been observed. PSRCC is characterized by numerous cells containing intracytoplasmic mucin and associated with aggressive clinical behavior, as opposed to extracellular mucin and favorable prognosis of MBC [ 1 , 2 , 10 – 15 ]. It is important to distinguish PSRCC from MBC, since it is believed that treatment options and the clinical outcome are different [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous Carcinoma

Zhang

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

Primary signet-ring cell carcinoma (PSRCC) of the breast is a rare entity and classified under mucin producing tumors in the WHO classification. However, little is known about the clinicopathological characteristics and clinical outcomes of PSRCC as opposed to mucinous carcinoma. Eleven patients with PSRCC in our center from 1995 to 2010 were evaluated in this study, as compared to 50 cases of mucinous breast cancer (MBC) during the same period. The clinicopathologic features of PSRCC compared to MBC were assessed. Furthermore, overall survival (OS) and disease-free survival (DFS) were calculated at 5 years of follow up. Patients with PSRCC showed more frequent lymphatic metastasis, higher Ki67 labeling index and more advanced stage disease than that of MBC (P = 0.018, p = 0.023, P = 0.000, respectively), although there was no difference in age, tumor size, and ER, PR expression between PSRCC and MBC. In addition, PSRCC was associated with simultaneous vimentin upregulation and E-cadherin downregulation. The 5-year OS of PSRCC (54.5%) was significantly lower than that of MBC (88%) (P = 0.004). Similarly, the DFS of PSRCC was poorer than that of MBC significantly (5-year DFS: 27.3% vs. 80%, P = 0.000).ConclusionsOur results confirmed the more aggressive behavior of PSRCC compared to MBC. This tumor is frequently associated with more frequent lymphatic metastasis, higher Ki67 labeling index, more advanced stage disease as well as simultaneous vimentin upregulation and E-cadherin downregulation. Different management guidelines should be considered for the two types.

show abstract

“…SRCC of the breast is a rare entity, accounting for 2–4.5% of total breast carcinomas. Presentation as a pure SRCC in the breast is even more uncommon, with an unknown actual incidence [ 2 ]. To the best of our knowledge, there are no reported cases in which these two pathological rarities appear simultaneously.…”

Section: Introductionmentioning

confidence: 99%

A rare case of concurrent signet-ring carcinoma of breast and microangiopathic hemolytic anemia

et al. 2016

View full text Add to dashboard Cite

Microangiopathic hemolytic anemia (MAHA) can be an uncommon presentation of an underlying malignancy, most often due to signet-ring cell carcinoma (SRCC). Additionally, pure SRCC in a breast primary-tumor comprises <2% of all breast cancers (Shin SY, Park H, Chae SW, Woo HY. Microangiopathic hemolytic anemia as the first manifestation of metastatic signet-ring cell carcinoma of unknown origin: a case report and review of literature. Kor J Lab Med 2011;31:157–61). To the best of our knowledge, the combination of these two entities, pure breast primary SRCC along with MAHA, has not been reported. Here, we present such a rare case. We also evaluate the current literature regarding this and similar disease processes, of which evidence is scarce and further research is needed.

show abstract

Pure primary signet ring cell carcinoma breast: A rare cytological diagnosis

Cited by 6 publications

References 8 publications

Prognostic Analysis of Primary Breast Signet Ring Cell Carcinoma and Mucinous Breast Adenocarcinoma: A SEER Population-Based Study

Prognostic Analysis of Primary Breast Signet Ring Cell Carcinoma and Mucinous Breast Adenocarcinoma: A SEER Population-Based Study

Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous Carcinoma

A rare case of concurrent signet-ring carcinoma of breast and microangiopathic hemolytic anemia

Contact Info

Product

Resources

About